Pressure Ulcer Clinical Trial
Official title:
Insulin Complexation With Hydroxypropyl-beta-cyclodextrin: Spectroscopic Evaluation of Molecular Inclusion and Use of the Complex in Gel for Healing of Pressure Ulcers
Verified date | December 2015 |
Source | State University of Maringá |
Contact | n/a |
Is FDA regulated | No |
Health authority | Brazil: Ministry of Health |
Study type | Interventional |
The coprecipitation method was used to prepare hydroxypropyl-beta-cyclodextrin complexed
with insulin (HPβCD-I) by mixing insulin with hydroxypropyl-beta-cyclodextrin (HPβCD) in the
molar ratio of 1:5 with the addition of 10 mL of purified water for every 100 mg of the
complex. After complete dissolution of the material, the mixture was stirred for 30 min at
room temperature (25°C), then left to rest for 60 min and lyophilized.
The gel was prepared by dispersing the Carbopol 940® polymer in a known amount of purified
water. Under mild heating the methylparaben (0.02%, w/v), propylparaben (0.01%, w/v) and
propylene glycol were dissolved and incorporated in the dispersion of Carbopol 940® and left
to rest for a period of 12h. After this time, the prepared gel was stirred and pH corrected
to a range of 5.0 to 7.0 with triethanolamine. A set amount of insulin and the HPβCD-I
complex were incorporated into the control gel for the preparation of other formulations.
A randomized, double-blind, prospective clinical trial was conducted from March 2013 to
April 2014 at the Hospital Universitário Regional de Maringá (HUM), Paraná, Brazil, in order
to determine the safety and efficacy of gel in patients hospitalized in the Intensive Care
Unit.
Hyperglycemic volunteers and those with pressure ulcers other than grade II were excluded
from the study. Grade II pressure ulcers were selected as they are a superficial lesion,
with little tissue loss, and allow easy visualization of healing.
A letter of free and informed consent was obtained. The study was conducted with each
patient for a period of 15 days.
The volunteers were divided equally into three groups A, B and C, with each group being
formed by five volunteers (n=5). Group A was randomly selected for treatment with gel with
HPβCD-I complex, group B for treatment with gel with insulin, and group C with the control
gel.
Blood glucose tests were performed in order to assess whether the insulin complexed or
otherwise with HPβCD could cause an increase in the rate of insulin in the blood in
patients, leading to hypoglycemia.
An identical standardized procedure for gel placement was used for all patients. Initially,
the pressure ulcer was cleaned with saline. With the aid of a paper ruler, the ulcer was
measured and photographed, as the ruler included the date and the initials of the patient.
After measuring, a quantity of 5 grams of gel was placed on the pressure ulcer and covered
with sterile gauze and a transparent film.
The curative was changed once a day during the treatment period, unless there was leakage of
fluid, contamination, or signs of infection. Every three days the pressure ulcers of all
patients were measured and photographed again, resulting in a total of six measurements per
patient. The photos of pressure ulcers were evaluated for measurement of pressure ulcers and
any kind of irritation. At the end of this stage, the properly gathered study data was
interpreted using the analysis software Mobile Wound Analyzer® (MOWA).
Data was evaluated by variance analysis (ANOVA), and means were compared with the Tukey test
(p < 0.05) using the software Statistica 8.0/2008 (Stat Soft Inc., Tulsa, USA).
Mixed model repeated measures methodology with some covariance structures was adopted for
statistical analysis of the clinical trial (p < 0.05). The Statistical Analysis System (SAS)
for Windows, version 9.3 (SAS Inc., Chicago, IL) program was used for statistical analysis.
Status | Completed |
Enrollment | 15 |
Est. completion date | July 2014 |
Est. primary completion date | April 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 45 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Brazilian, - bedridden, - of both genders, - aged between 45 and 75 years old, and - diabetic or not. Exclusion Criteria: - hyperglycemic volunteers, and - those with pressure ulcers other than grade II. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
State University of Maringá | Conselho Nacional de Desenvolvimento Científico e Tecnológico, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior., Financiadora de Estudos e Projetos, Fundação Araucária |
Chaudhary H, Rohilla A, Rathee P, Kumar V. Optimization and formulation design of carbopol loaded Piroxicam gel using novel penetration enhancers. Int J Biol Macromol. 2013 Apr;55:246-53. doi: 10.1016/j.ijbiomac.2013.01.015. Epub 2013 Jan 31. — View Citation
Siritientong T, Angspatt A, Ratanavaraporn J, Aramwit P. Clinical potential of a silk sericin-releasing bioactive wound dressing for the treatment of split-thickness skin graft donor sites. Pharm Res. 2014 Jan;31(1):104-16. doi: 10.1007/s11095-013-1136-y. Epub 2013 Jul 31. — View Citation
Zhang L, Zhu W, Song L, Wang Y, Jiang H, Xian S, Ren Y. Effects of hydroxylpropyl-ß-cyclodextrin on in vitro insulin stability. Int J Mol Sci. 2009 May 6;10(5):2031-40. doi: 10.3390/ijms10052031. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Efficacy Index (%EI) | Every three days the pressure ulcers (PUs) of all patients were measured and photographed again, resulting in a total of six measurements per patient. The photos were evaluated for measurement of PUs and any kind of irritation. At the end of this stage, the properly gathered study data was interpreted using the analysis software Mobile Wound Analyzer® (MOWA). Healing efficacy indices (% EI) were calculated as percentage reduction in the wound size at days 3, 6, 9, 12 and 15 from treatment beginning (d0). The % EI of the wound size was calculated by the following equation: %EI= ((Vsp.day-Vi)/Vi))x100. Vsp.day refers to the diameter (mm) values measured at day 3, 6, 9,12 and 15, while Vi refers to the baseline value measured before treatment (d0). The most representative result of treatment efficacy was observed on day 15, therefore it was used to calculate the % EI. For each group assessed, it was calculated the mean % EI of the five patients, resulting in a single value. | Measured every 3 days for 15 days | No |
Secondary | Blood Glucose Tests in Order to Assess Whether the Gel With Hydroxypropyl-beta-cyclodextrin Complexed With Insulin (HPßCD-I) or With Insulin Could Cause an Increase in the Rate of Insulin in the Blood of Patients | Dosages were provided four times daily (04h, 10h, 16h and 22h) to each patient during the 15-day study period, giving a total of 60 doses. To obtain these dosages, a drop of blood of patients was placed on a colorimetric strip and blood glucose was measured with the use of an Accu Check Active® glucose meter. The mean of 60 dosages was calculated for each patient at the end of 15 days. For each group assessed, it was calculated the mean of the measurements of the five patients, resulting in a single value. | Assessed daily at 04 h, 10 h, 16 h and 22 h for 15 days | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03351049 -
An RCT on Support Surfaces for Pressure Ulcer Prevention
|
N/A | |
Completed |
NCT05112068 -
Comparative Assessment of Effectiveness and Safety of Methods for Skin and Hair Care in Severe Intensive Care Unit Patients
|
||
Completed |
NCT05575869 -
Evaluation of the Impact of the PRONEtect Education Hub vs. Classic Lecture, on the Competencies of Nursing Students
|
N/A | |
Completed |
NCT03220451 -
Use of Adhesive Elastic Taping for the Therapy of Medium/Severe Pressure Ulcers in Spinal Cord Injured Patients
|
N/A | |
Terminated |
NCT05234632 -
Study to Evaluate the PICO 14 Negative Pressure Wound Therapy System in the Management of Acute and Chronic Wounds
|
N/A | |
Completed |
NCT04540822 -
Peripheral Catheter Pressure Ulcer Prevention in Pediatry : Use of Compresses Versus Standard Care
|
N/A | |
Terminated |
NCT01966380 -
Proof of Concept (Design Validation) in Patient With Hard to Heal Wounds Such as Pressure Ulcer, Diabetic Foot Ulcer and Leg Ulcer, Leia
|
Phase 2 | |
Completed |
NCT02092870 -
Adipose Derived Regenerative Cellular Therapy of Chronic Wounds
|
Phase 2 | |
Completed |
NCT01438541 -
A Multi-centre Evaluation of the Performance of Window Dressings on Subjects With High Risk Pressure Ulceration
|
Phase 4 | |
Completed |
NCT00365430 -
SAFE or SORRY? Patient Safety Study of the Prevention of Adverse Patient Outcomes
|
N/A | |
Completed |
NCT04251897 -
Novel Support Surface to Alleviate Pressure Ulcer
|
N/A | |
Completed |
NCT03391310 -
Use of Honey for Pressure Ulcers in Critically Ill Children
|
N/A | |
Recruiting |
NCT04559165 -
Efficacy and Safety of Sericin and Chitosan Cream for Preventing and Limiting the Progressive of Pressure Sore
|
N/A | |
Completed |
NCT05646121 -
Suprasorb® A + Ag in the Treatment of Wounds at Risk of Infection and Infected Wounds
|
||
Not yet recruiting |
NCT06421454 -
Clinical Trial for the Evaluation of Melatonin in the Treatment of Pressure Ulcers
|
N/A | |
Terminated |
NCT05547191 -
Evaluate Efficacy and Safety of ChloraSolv When Treating Pressure Ulcers in Need of Debridement
|
N/A | |
Completed |
NCT05458050 -
An Investigation to Identify Subjects Admitted to Hospital With an Increased Risk of Developing Pressure Ulcers
|
N/A | |
Active, not recruiting |
NCT03048357 -
Effectiveness of Freedom Bed Compared to Manual Turning in Prevention of Pressure Injuries in Persons With Limited Mobility Due to Traumatic Brain Injury and/or Spinal Cord Injury.
|
N/A | |
Completed |
NCT06025370 -
Pressures During Prone Positions in Healthy Volunteers
|
N/A | |
Recruiting |
NCT05033470 -
A Multicentre Prospective Study Evaluating an Off-loading Mattress Overlay System in Healing of Stage 3 Pressure Ulcers
|
N/A |